Skip to Main Content
Contribute Try STAT+ Today

The Senate will soon begin the process of considering President Trump’s nomination of Dr. Scott Gottlieb, who has close professional and financial ties with the pharmaceutical and biotechnology industries, for commissioner of the Food and Drug Administration. A trial that began in a federal courtroom in Boston in January is a timely reminder of how the laissez-faire regulatory posture that Gottlieb is expected to promote can harm the public’s health.

The Boston trial involves the first of more than a dozen employees of New England Compounding Center (NECC) who distributed steroids contaminated with fungi. These caused infections that led to 64 deaths and more than 700 cases of illness or disability in 20 states in 2012 and 2013. The NECC employees now face charges that include fraud, murder, and violating federal laws. They exploited weaknesses in FDA oversight. The company essentially became a manufacturer of prescription medications without following the FDA’s requirements for manufacturers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This article fails to address the biggest concern over Gottlieb, who works for venture capital firm NEA (New Enterprise Associates), who have pathologically funded startup medical device fraud which had cost taxpayers millions if not billions & patients their health if not lives. It’s like putting the fox in the hen house, killing patients faster.
    NEA funded, in-part, Conceptus, now Bayer’s Essure, Gynecare, now Johnson & Johnson’s Gynecare or Women’s Health and Acclarent, where a fraudulent medical device was removed from the market. The acquiring company also Johnson & Johnson knowingly & willingly continued the fraud until the FCA forced the device off market, cost JNJ $18 million in civil damages and two former executives were convicted of selling a misbranded medical device and currently awaiting sentencing under Judge Allison Burroughs in Boston. NEA funded and profited from medical device fraud, leaving a trail of injured bodies without any accountability. Gottlieb is the last person taxpayers should want to head FDA.

Comments are closed.